A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer

Lerner, A.; Keshwani, Karim; Okines, Alicia; Sanderson, Benjamin M.; Board, Ruth; Flynn, Michael J.; Sharkey, Elizabeth; Konstantis, Apostolos; Roylance, Rebecca; Hanna, Daire; King, James P.; Murphy, Ronan A.; Rehman, Farah L.; Guppy, Amy; Westbury, Charlotte; Takeuchi, Elena; Spurrell, Emma; Jayaweera, H K; Raja, F.

doi:10.1016/j.clon.2021.12.012

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, combining AI with a CDK4/6 inhibitor gained importance in the treatment of hormone receptor-positive advanced breast cancer. This combination consistently improved PFS compared to AIs alone [36,37]. Along with these results, other approaches aimed at improving outcomes were previously developed.…”

Section: Discussionmentioning

confidence: 83%

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

et al. 2023

View full text Add to dashboard Cite

(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We performed a retrospective study to confirm the efficacy and expand the safety data for capecitabine plus AI (a combination henceforth named XELIA) for this indication. (2) We conducted a single-center retrospective cohort study of 163 hormone receptor-positive metastatic breast cancer patients who received either the XELIA regimen, capecitabine, or an aromatase inhibitor (AI) as single agents in first-line treatment. The primary endpoint was progression-free survival, and the secondary endpoints were overall survival, best objective response, and toxicity incidence. (3) Results: the median progression-free survival for patients receiving XELIA, AI, and capecitabine was 29.37 months (20.91 to 37.84; 95% CI), 20.04 months (7.29 to 32.80; 95% CI) and 10.48 (8.69 to 12.28; 95% CI), respectively. The overall response rate was higher in the XELIA group (29.5%) than in the AI (14.3%) and capecitabine (9.1%) groups. However, the differences in overall survival were not statistically significant. Apart from hand–foot syndrome, there were no statistically significant differences in adverse events between the groups. (4) Conclusions: this retrospective study suggests that progression-free survival and overall response rates improved with the XELIA regimen compared to use of aromatase inhibitors and capecitabine alone. Combined use demonstrated an adequate safety profile and might represent an advantageous treatment in places where CDK 4/6 is not available. Larger studies and randomized clinical trials are required to confirm the effects shown in our study.

show abstract

Section: Discussionmentioning

confidence: 83%

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…FUL is a selective ER down-regulator that effectively prevents endogenous estrogen from binding to the ER. This action obstructs ER dimerization as well as DNA binding, enhances ER turnover to impede the receptor’s nuclear uptake, and promotes proteasomal degradation, consequently inhibiting tumor cell proliferation ( 20 ). Approved for HR+ advanced BC and postmenopausal women experiencing disease progression post anti-estrogen therapy ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review

Zhang,

Luo,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundEarly studies have revealed antagonistic effects associated with stacking chemotherapy (CT) and endocrine therapy (ET), thereby conventional wisdom does not advocate the simultaneous combination of these two treatment modalities. Limited clinical studies exist on the combined use of neoadjuvant CT (NACT) and neoadjuvant ET (NET), and there are no reported instances of concurrent neoadjuvant treatment for locally advanced breast cancer (LABC) using capecitabine and fulvestrant (FUL).Case presentationWe reported a 54-year-old woman who was diagnosed with hormone receptor-positive (HR+) LABC at our hospital. After neoadjuvant treatment involving two distinct CT regimens did not lead to tumor regression. Consequently, the patient was transitioned to concurrent capecitabine and FUL therapy. This change resulted in favorable pathological remission without any significant adverse events during treatment.ConclusionsA novel approach involving concurrent neoadjuvant therapy with CT and endocrine therapy may offer a potentially effective treatment avenue for some cases with HR+ LABC.

show abstract

Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?

Zhang,

Pan,

Weng

et al. 2024

Clinical Breast Cancer

View full text Add to dashboard Cite

A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer

Cited by 3 publications

References 10 publications

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review

Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?

Contact Info

Product

Resources

About